Abstract:Schizophrenia and related mood disorders are complex psychiatric disorders that affect ~2% of the population ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar ). The fortuitous finding of chlorpromazine and other phenothiazines in the early 1950s and subsequent development of clozapine and related antipsychotic drugs ameliorated a subset of syndromes of psychosis and resulted in deinstitutionalization of many patients with psychiatric disorders. The drugs seem to benefit patients by modulating dopaminergic or serotoninergic function, or both. The exact mechanisms of action of the drugs are unknown. There are still no good answers 50 years after the discovery of these drugs as to why the medications fail to treat the negative symptoms and cognitive deficits, and this lack of answers has hampered the development of more effective medications ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar ). A comprehensive understanding of the etiopathology of psychiatric disorders is urgently needed for developing improved medications. Accumulating research findings have fostered a hypothesis that aberrant glutamatergic transmission, particularly aberrant N-methyl-D-aspartate receptor (NMDAR)–mediated glutamate transmission, may be responsible for schizophrenia and related psychiatric disorders ( 1 Brandon N.J. Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011; 12: 707-722 Google Scholar , 2 Moghaddam B. Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15 Google Scholar , 3 Harrison P.J. Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005; 10: 40-68 Google Scholar , 4 Lau C.G. Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8: 413-426 Google Scholar ). The initial evidence has emerged from administration of NMDAR antagonists, including phencyclidine and ketamine, which elicit psychotic symptoms and cognitive dysfunction similar to those of schizophrenia and related psychiatric disorders and aggravate the psychotic symptoms in patients with the disorders. The effects of NMDAR antagonists persist in the absence of activity of monoamines. Additionally, genetically reducing NMDAR expression in interneurons produces schizophrenia-like phenotypes. Finally, more recent genetic studies have linked numerous genes, including the disrupted in schizophrenia 1 gene (DISC1), with the disorders, and many of those molecules have been implicated in regulation of glutamatergic transmission ( 3 Harrison P.J. Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005; 10: 40-68 Google Scholar , 4 Lau C.G. Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8: 413-426 Google Scholar ). Together, these findings have led to the prevailing hypothesis that hypofunction of NMDARs, particularly hypofunction of NMDARs in interneurons, causes progression and symptoms of schizophrenia and related psychiatric disorders. Regulation of N-Methyl-D-Aspartate Receptors by Disrupted-in-Schizophrenia-1Biological PsychiatryVol. 75Issue 5PreviewGenetic studies have implicated disrupted-in-schizophrenia-1 (DISC1) as a risk factor for a wide range of mental conditions, including schizophrenia. Because N-methyl-D-aspartate receptor (NMDAR) dysfunction has been strongly linked to the pathophysiology of these conditions, we examined whether the NMDAR is a potential target of DISC1. Full-Text PDF

Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity Via D2 Receptors

A Dopamine D2 Receptor-Disc1 Protein Complex May Contribute to Antipsychotic-Like Effects.

HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice

Prevention of Neurite Spine Loss Induced by Dopamine D2 Receptor Overactivation in Striatal Neurons

A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth

Disrupted‐in‐schizophrenia‐1 Protects Synaptic Plasticity in a Transgenic Mouse Model of Alzheimer’s Disease As a Mitophagy Receptor

Disrupted-in-Schizophrenia-1 Attenuates Amyloid- β Generation and Cognitive Deficits in APP/PS1 Transgenic Mice by Reduction of β -Site APP-Cleaving Enzyme 1 Levels

The D2R-DISC1 Protein Complex and Associated Proteins Are Altered in Schizophrenia and Normalized with Antipsychotic Treatment.

Structural Interaction Between DISC1 and ATF4 Underlying Transcriptional and Synaptic Dysregulation in an Ipsc Model of Mental Disorders

THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia

DISC1 Dynamically Regulates Synaptic N-Methyl-D-Aspartate Responses in Excitatory Neurons

Aripiprazole and Haloperidol Protect Neurite Lesions Via Reducing Excessive D2R-DISC1 Complex Formation.

Dopamine–endocannabinoid Interactions Mediate Spike-Timing-dependent Potentiation in the Striatum

Bdnf Rescues Prefrontal Dysfunction Elicited By Pyramidal Neuron-Specific Dtnbp1 Deletion In Vivo

Disrupted-in-schizophrenia 1 Protein Misassembly Impairs Cognitive Flexibility and Social Behaviors in a Transgenic Rat Model

Targeting the D1-N-methyl-D-aspartate Receptor Complex Reduces L-dopa-induced Dyskinesia in 6-Hydroxydopamine-lesioned Parkinson’s Rats

Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation

Identification and Mechanistic Characterization of a Peptide Inhibitor of Glycogen Synthase Kinase (GSK3β) Derived from the Disrupted in Schizophrenia 1 (DISC1) Protein

The Allosteric Dopamine D1 Receptor Potentiator, DETQ, Ameliorates Subchronic Phencyclidine-Induced Object Recognition Memory Deficits and Enhances Cortical Acetylcholine Efflux in Male Humanized D1 Receptor Knock-in Mice.

Blocking Src-PSD-95 interaction rescues glutamatergic signaling dysregulation in schizophrenia

Effects of DISC1 on Alzheimer's disease cell models assessed by iTRAQ proteomics analysis